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Abstract: Oxyresveratrol has been proven effective in inhibiting adipogenesis in a 3T3-L1 cell model.
We investigated the preventive effect of oxyresveratrol supplementation on obesity development in
high-fat diet-fed mice. Male C57bl/6 mice were randomly subjected to control (5% fat by weight, LF),
high-fat (30% fat by weight, HF), and high-fat supplemented with 0.25% and 0.5% oxyresveratrol
(OXY1 and OXY2, respectively) diet groups for eight weeks. Oxyresveratrol supplementation effectively
alleviated obesity-associated symptoms such as insulin resistance, hyperglycemia, and hepatic steatosis
in high-fat diet-fed mice. Compared to the high-fat diet group, oxyresveratrol supplementation
suppressed expression of glucose-6-phosphatase, sterol regulatory element-binding proteins 1, fatty
acid synthase and CCAAT/Enhancer-binding proteins α, and elevated AMP-activated protein kinase
(α2-catalytic subunit) level in liver, upregulated insulin-dependent glucose transporter type 4 level
in adipose tissue, and increased expression of insulin receptor substrate 1, insulin-dependent
glucose transporter type 4, AMP-activated protein kinase α, peroxisome proliferator-activated
receptor γ coactivator-1α, and sirtuin 1 in muscle to regulate lipid and glucose homeostasis in
these tissues. This study demonstrated that oxyresveratrol supplementation effectively ameliorated
obesity-associated symptoms in high-fat diet-fed mice, presumably attributed to mediating critical
regulators involved in lipid and glucose homeostasis in liver, visceral fat, and muscle.
Keywords: oxyresveratrol supplementation; amelioration; high-fat diet; obesity; glucose homeostasis;
lipid homeostasis
1. Introduction
Over the years, the prevalence of obesity has been increasing worldwide with the obese population
more than doubling since 1980. Around the world, more than 1.9 billion adults were overweight or
obese in 2014. Additionally, in 2014, 41 million children under the age of 5 were reported to suffer
from overweight or obesity [1]. More and more adults as well as children suffer from abnormal
or excessive body fat with a variety of comorbidities, such as hypertension, dyslipidemia, type 2
diabetes, cardiovascular disease, stroke, sleep apnea, knee osteoarthritis, and certain cancers [2,3].
Obesity has been considered a global epidemic disease [1,4]. Soaring demands for effective anti-obesity
strategies are driving industry and academia to conduct research in this field. To prevent or heal
obesity with the supplementation of phenolic compounds have generated intense interest in recent
years. Among the studied phenolics, resveratrol (Figure 1a) has been extensively studied with both
in vitro and in vivo studies demonstrating that resveratrol has great potential in the management
of obesity. Supplementation of resveratrol is capable of relieving the harmful effects induced by
a high-calorie diet such as reducing the rodents body weight gain, adipose tissue depots, plasma
triglycerides, and increasing their survival and motor function [5].
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Being similar in structure with resveratrol, oxyresveratrol (OXY) (Figure 1b) possesses
an additional hydroxyl group on its aromatic ring [6,7]. OXY is a natural polyphenol first isolated from
the heartwood of Artocarpus lakoocha Roxb and also rich in mulberry (Morus alba L.) twigs and woods [8].
Studies on OXY have revealed that it possesses similar biological activities as resveratrol and the
potential beneficial effects include anti-inflammatory, anti-oxidative, anti-viral, and neuroprotective
activities [9–14]. It has also been considered a potent free radical scavenger, a tyrosinase inhibitor,
and an anti-browning agent that could be used in food industry for cloudy apple juices and fresh-cut
apples [7,15,16].
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Figure 1. Structures of resveratrol (a) and oxyresveratrol (b). 
Our previous study demonstrated that OXY, at non‐cytotoxic doses, possesses anti‐adipogenic 
ability  in  3T3‐L1  cells  by  inhibition  of  differentiation  through  inducing  cell  cycle  arrest  [17]. 
However, little is known about OXY’s impact on obesity in vivo. The present study thus aimed at 
investigating the preventive effects of OXY supplementation on the development of obesity in mice 
fed with a high‐fat diet. C57bl/6 male mice were randomly assigned to control (5% fat by weight, 
LF), high‐fat  (30%, HF), and high‐fat supplemented with 0.25% and 0.5% OXY  (OXY1 and OXY2, 
respectively) diet groups  for eight weeks. Growth parameters, organ and adipose  tissue weights, 
serum  biochemical  parameters,  and  the  expressions  of  relevant mRNA/protein  in  liver,  adipose 
tissues, and muscles were  examined  to  identify  the putative anti‐obesity  effect of OXY and gain 
insight on the underlying mechanism. 
2. Materials and Methods   
2.1. Oxyresveratrol and Experimental Diets 
OXY (≥98% pure, CAS registry No. 29700‐22‐9) was purchased from Great Forest Biomedical 
Ltd., Hangzhou, China. The purity was confirmed by High Performance Liquid Chromatography 
analysis. 
The  formulation  for  the  experimental  diets  was  modified  based  on  the  AIN‐93G 
recommendation [18]. The control diet was the low‐fat diet (LF, 5% fat w/w) that comprised corn oil 
(50 g/kg) as  lipids. The high‐fat diet  (HF, 30%  fat w/w) comprised corn oil  (150 g/kg) and Crisco 
shortening (150 g/kg) as lipids. The two treatment groups were the high‐fat diets supplemented with 
0.25% OXY (OXY1) and 0.5% OXY  (OXY2). OXY was added  to  the high‐fat diet at  the expense of 
cornstarch. OXY1 and OXY2 diets contained 2.5 g and 5 g OXY/kg, respectively. Diet compositions 
with energy density were stated in Table 1. All prepared diets were stored at −40 °C and fresh diets 
were provided every other day. 
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Figure 1. Structures of resveratrol (a) and oxyresveratrol (b).
Our previous study demonstrated that OXY, at non-cytotoxic doses, possesses anti-adipogenic
ability in 3T3-L1 cells by inhibition of differentiation through inducing cell cycle arrest [17].
However, little is known about OXY’s impact on obesity in vivo. The present study thus aimed at
investigating the preventive effects of OXY supplementation on the development of obesity in mice
fed with a high-fat diet. C57bl/6 male mice were randomly assigned to control (5% fat by weight,
LF), high-fat (30%, HF), and high-fat supplemented with 0.25% and 0.5% OXY (OXY1 and OXY2,
respectively) diet groups for eight weeks. Growth parameters, organ and adipose tissue weights, serum
biochemical parameters, and the expressions of relevant mRNA/protein in liver, adipose tissues, and
muscles were examined to identify the putative anti-obesity effect of OXY and gain insight on the
underlying mechanism.
2. Materials and Methods
2.1. Oxyresveratrol and Experimental Diets
OXY (≥98% pure, CAS registry No. 29700-22-9) was purchased from Great Forest Biomedical Ltd.,
Hangzhou, China. The purity was confirmed by High Performance Liquid Chromatography analysis.
The formulation for the experimental diets was modified based on the AIN-93G
recommendation [18]. The control diet was the low-fat diet (LF, 5% fat w/w) that comprised corn oil
(50 g/kg) as lipids. The high-fat diet (HF, 30% fat w/w) comprised corn oil (150 g/kg) and Crisco
shortening (150 g/kg) as lipids. The two treatment groups were the high-fat diets supplemented with
0.25% OXY (OXY1) and 0.5% OXY (OXY2). OXY was added to the high-fat diet at the expense of
cornstarch. OXY1 and OXY2 diets contained 2.5 g and 5 g OXY/kg, respectively. Diet compositions
with energy density were stated in Table 1. All prepared iets were stored at −40 ◦C and fresh diets
were provided every other day.
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Table 1. Composition of the experimental diets 1.
Ingredient LF 2 HF 3 OXY1 4 OXY2 5
g/kg
Casein 6, 87.5% 200 235 235 235
Corn starch 6 549.5 255.5 253 250.5
Sucrose 6 100 100 100 100
Cellulose (fiber) 6 50 50 50 50
Crisco 7 0 150 150 150
Corn oil 8 50 150 145 145
Oxyresveratrol 0 0 2.5 5
Mineral 6, AIN-93G-MX 35 42 42 42
Vitamin 6, AIN-93-VM 10 12 12 12
Choline bitartrate 2.5 2.5 2.5 2.5
L-Cystine 3 3 3 3
Tert-butylhydroquinone 0.014 0.014 0.014 0.014
Energy 9, kJ/g 15.69 20.69 20.46 20.42
1 Based on AIN-93G diet with modification. 2 LF: Low-fat diet. 3 HF: High-fat diet. 4 OXY1: High-fat diet
supplemented with 0.25% oxyresveratrol. 5 OXY2: High-fat diet supplemented with 0.5% oxyresveratrol. 6 Harlan
Teklad (Madison, WI, USA). 7 Crisco, partially hydrogenated vegetable shortening (Procter & Gamble, Orrville,
OH, USA). 8 Mazola (CPC, Kuala Lumpur, Malaysia). 9 Based on energy densities: 16.74 kJ/g for protein and
carbohydrates and 37.66 kJ/g for fat.
2.2. Experimental Design
39 male C57bl/6 mice, four weeks of age, were obtained from the animal unit of Faculty of
Medicine, The University of Hong Kong, Hong Kong. The animals were housed individually under
controlled temperature and 12 h light-dark cycle and had free access to water. The mice were randomly
assigned to one of the four diet groups (n = 8–11) for eight weeks: low-fat diet (LF, 5% fat w/w); high-fat
diet (HF, 30% fat w/w); high-fat diets supplemented with 0.25% OXY (OXY1) and 0.5% OXY (OXY2).
Food intake and body weight were monitored every other day. At the end of eight weeks, blood was
drawn from the abdominal vena cava from each mouse and then the mouse was killed by cervical
dislocation. Tissues including liver, visceral fat, and gastrocnemius muscle were collected and stored
at −80 ◦C for assays of biochemical parameters, and gene/protein expression. All the procedures were
performed with the approval of the ethics committee on the Use of Live Animals in Teaching and
Research at The University of Hong Kong (No. 3263-14).
2.3. Measurement of Biochemical Parameters
Serum was prepared by leaving the blood to clot undisturbed at room temperature for 30 min and
then removing the clot by centrifuging at 2000 g for 10 min at 4 ◦C. Serum glucose was determined
by Glucose Assay Kit (Abcam, Cambridge, UK). Serum high-density lipoprotein (HDL) cholesterol
was assayed by Cholesterol, HDL Test, Precipitating Reagent (Stanbio Laboratory, Boerne, TX, USA).
Cholesterol was determined with Cholesterol LiquiColor (Stanbio Laboratory, Boerne, TX, USA).
Serum insulin was measured by Mercodia Mouse Insulin ELISA kit (Mercodia, Uppsala, Sweden).
The HOMA-IR (homeostasis model assessment of insulin resistance) index was calculated as (fasting
serum glucose (mmol/L) × fasting serum insulin (mIU/L)/22.5) to assess insulin resistance [19,20].
Serum and liver triglyceride (TG) were assayed using Triglycerides LiquiColor (Stanbio Laboratory,
Boerne, TX, USA). Non-esterified fatty acid (NEFA) was measured by LabAssay NEFA kit (Wako Pure
Chemical Industries, Osaka, Japan).
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2.4. Total RNA Isolation and Real-Time Reverse Transcriptase Polymerase Chain Reaction (PT-PCR) Analysis
Total RNA from liver, visceral fat, and gastrocnemius muscle were extracted with Trizol reagent
(Invitrogen, Waltham, MA, USA) following the manufacturer’s instructions. cDNA was synthesized
from 0.5 µg of total RNA using iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA). cDNA and TaqMan probes were subjected to quantitative Real-Time PCR amplification
by TaqMan Universal Master Mix II (Applied Biosystems, Carlsbad, CA, USA) on the StepOnePlus
Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). The thermal profile settings were
50 ◦C for 2 min and 95 ◦C for 10 min and then 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min.
Relative expression levels of the mRNA of the target genes were normalized to GAPDH mRNA levels.
2.5. Protein Extraction and Western Blotting Analysis
Mice liver tissue fragments were homogenized in an ice cold lysis buffer (25 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 150 mM sodium chloride, 1 mM
ethylenediaminetetraacetic acid disodium salt, 1 mM dithiothreitol, 1% Triton X-100) with added
4% protease inhibitor cocktail, 1% phosphatase inhibitor cocktail B, and 2% phosphatase inhibitor
cocktail C for protein collection. Protein concentration in samples was determined using the Bradford
Reagent (Bio-Rad Protein Assay Dye Reagent Concentrate). 30 µg of protein of each sample was
applied for electrophoresis on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels
and transferred to polyvinylidene diflouride membrane. Membranes were blocked with 5% nonfat
dried milk powder in phosphate buffered saline (PBS) solution with tween-20 or tris buffered saline
(TBS) solution with tween-20 (0.1% v/v tween-20 in PBS or TBS) overnight at 4 ◦C. The membranes
were then incubated for 2 h with specific antibodies at room temperature. Equal sample loading was
verified by anti-β-actin. Membranes were developed using SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology, Rockford, IL, USA). The bands were quantified densitometrically
using the software ImageJ 1.47v (Wayne Rasband, Bethesda, MD, USA).
2.6. Statistical Analysis
The data were presented as means ± S.E.M. (the standard error of the mean). One-way ANOVA
with Duncan corrections was used to determine significance for multiple comparisons. For all analyses,
the accepted level of significance was p < 0.05. The calculations were performed using SPSS statistical
package version 11.0 for Windows (International Business Machines Corporation, Armonk, NY, USA).
3. Results
3.1. Effects of Oxyresveratrol on Body Weight, Energy Intake, Energy Efficiency, and Tissue Weights
After feeding with designated diets for eight weeks, the HF mice had significantly higher body
weight gain, energy intake and energy efficiency than that of the LF mice (Figure 2, Table 2, p < 0.05).
While, OXY supplemented high-fat feeding mice (OXY1, OXY2) had significantly reduced body weight
gain, energy intake and energy efficiency as compared to those of the HF mice (Figure 2, Table 2,
p < 0.05). Comparing the two OXY supplemented groups, both body weight gain and energy efficiency
were significantly lower in the OXY2 group, while energy intakes were not significantly different
(Figure 2, Table 2, p < 0.05). Furthermore, as indicated in Table 2, there was no significant difference
in gastrocnemius muscle weights among the four groups, while the weights of liver and visceral fat
in OXY1 and OXY2 mice were significantly reduced as compared to those of the HF mice (Table 2,
p < 0.05).
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eight weeks. Values  are presented  as means  ±  S.E.M. Means by different  letters  are  significantly 
different at p < 0.05. 
Table 2. Effects of oxyresveratrol supplementation on body weight, energy intake, energy efficiency, 
and tissue weights of mice 1,2. 
Parameters  LF 3 HF 4 OXY1 5  OXY2 6
Body weight 
Starting body weight, g  19.61 ± 0.21  19.71 ± 0.20  19.56 ± 0.25  19.56 ± 0.31 
Final body weight, g  32.46 ± 0.84 b  40.54 ± 0.71 a  33.51 ± 0.82 b  29.92 ± 0.93 c 
Body weight gain, g  12.85 ± 0.81 b  20.83 ± 0.67 a  13.95 ± 0.79 b  10.35 ± 0.77 c 
Energy intake   
Fat intake, MJ  0.43 ± 0.01 c  2.09 ± 0.02 a  1.89 ± 0.02 b  1.84 ± 0.05 b 
Energy intake, MJ  3.57 ± 0.05 b  3.82 ±0.04 a  3.49 ± 0.04 bc  3.37 ± 0.09 c 
Energy efficiency 7, g/MJ  3.60 ± 0.00 b 5.45 ± 0.00 a 3.98 ± 0.00 b  3.04 ± 0.00 c
Tissue weights         
Liver, g  1.12 ± 0.04 b  1.34 ± 0.07 a  1.08 ± 0.04 bc  0.96 ± 0.04 c 
Visceral fat, g  1.75 ± 0.13 c 3.31 ± 0.07 a 2.35 ± 0.15 b  1.60 ± 0.15 c
Gastrocnemius muscle, g  0.31 ± 0.03  0.29 ± 0.02  0.29 ± 0.01  0.30 ± 0.01 
1 Values are mean ± S.E.M. n = 8–11 per group at eight weeks. 2 Means in each row with superscripts 
without a common letter differ, p < 0.05. 3 LF: Low‐fat diet. 4 HF: High‐fat diet. 5 OXY1: High‐fat diet 
supplemented  with  0.25%  oxyresveratrol.  6  OXY2:  High‐fat  diet  supplemented  with  0.5% 
oxyresveratrol.  7 Energy  efficiency: body weight gain  (g)/energy  intake  (MJ). Energy  efficiency  is 
calculated as described by Li et al. [21]. 
3.2. Effects of Oxyresveratrol on Serum Concentration of Glucose and Insulin 
As  shown  in  Table  3,  the  serum  concentrations  of  glucose  and  insulin  in  HF  mice  were 
significantly higher than those of the LF mice;  the OXY supplementation significantly suppressed 
the levels of these two parameters in serum of high‐fat fed mice, and the serum  insulin  level was 
decreased to the level of the LF mice (Table 3, p < 0.05). Compared to that of other three groups, the 
HOMA‐IR index for the high fat group was significantly increased. Meanwhile, no difference in the 
HOMA‐IR index was observed among the OXY supplemented mice and the LF mice (Table 3, p < 
0.05). 
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Figure 2. Effects of xyresveratrol supplementation on body weight gain (a) and total energy intake (b).
C57 l/6 mice were f d low-fat or hig -fat diet with or without ox l (n = 8– 1/group) for
eight weeks. Values are presented as ea S.E. . Means by diff rent letters are significantly
different at p < 0. 5.
Table 2. Effects of oxyresveratrol supplementation on body weight, energy intake, energy efficiency,
and tissue weights of mice 1,2.
Parameters LF 3 HF 4 OXY1 5 OXY2 6
Body weight
Start g body weight, g 19.61 ± 0.21 19.71 ± .20 19.56 ± 0.25 19.56 ± 0.31
Final body weight, g 32.46 ± 0.84 b 40.54 ± 0.71 a 33.51 ± 0.82 b 29.92 ± 0.93 c
Body weight gain, g 12.85 ± 0.81 b 20.83 ± 0.67 a 13.95 ± 0.79 b 10.35 ± 0.77 c
Energy intake
Fat intake, MJ 0.43 ± 0.01 c 2.09 ± 0.02 a 1.89 ± 0.02 b 1.84 ± 0.05 b
Energy intake, MJ 3.57 ± 0.05 b 3.82 ±0.04 a 3.49 ± 0.04 bc 3.37 ± 0.09 c
Energy efficiency 7, g/MJ 3.60 ± 0.00 b 5.45 ± 0.00 a 3.98 ± 0.00 b 3.04 ± 0.00 c
Tissue weights
Liver, g 1.12 ± 0.04 b 1.34 ± 0.07 a 1.08 ± 0.04 bc 0.96 ± 0.04 c
Visceral fat, g 1.75 ± 0.13 c 3.31 ± 0.07 a 2.35 ± 0.15 b 1.60 ± 0.15 c
Gastrocnemius muscle, g 0.31 ± 0.03 0.29 ± 0.02 0.29 ± 0.01 0.30 ± 0.01
1 Values are mean ± S.E.M. n = 8–11 per group at eight weeks. 2 Means in each row with superscripts without
a common letter differ, p < 0.05. 3 LF: Low-fat diet. 4 HF: High-fat diet. 5 OXY1: High-fat diet supplemented with
0.25% oxyresveratrol. 6 OXY2: High-fat diet supplemented with 0.5% oxyresveratrol. 7 Energy efficie c : body
weight gain (g)/energy intake (MJ). Energy efficiency is calculated as described by Li et al. [21].
3.2. Effects of Oxyresveratrol on Serum Concentrati f l c se and Insulin
As shown in Table 3, the serum concentrations of glucose and insulin in HF mice were significantly
higher than those of the LF mice; the OXY supplementation significantly suppressed the levels of these
two parameters in serum of high-fat fed mice, and the serum insulin level was decreased to the level
of the LF mice (Table 3, p < 0.05). Compared to that of other three groups, the HOMA-IR index for
the high fat group was significantly increased. Meanwhile, no difference in the HOMA-IR index was
observed among the OXY supplemented mice and the LF mice (Table 3, p < 0.05).
3.3. Effects of Oxyresveratrol on Lipid Profiles in Serum and Liver
Compared to the HF group, 0.5% OXY supplementation to a high-fat diet for eight weeks
significantly lowered serum levels of TG, cholesterol, and NEFA and also liver levels of TG and
cholesterol (Table 3, p < 0.05).
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Table 3. Effects of oxyresveratrol supplementation on serum and liver biological parameters of mice 1,2.
Biological Parameters LF 3 HF 4 OXY1 5 OXY2 6
Serum
Glucose, mM 4.8 ± 0.4 c 9.6 ± 0.8 a 6.7 ± 0.6 b 7.2 ± 0.3 b
Insulin, µg/L 0.5 ± 0.3 b 1.5 ± 0.3 a 0.4 ± 0.1 b 0.3 ± 0.2 b
HOMA-IR index 7 4.4 ± 1.7 b 20.1 ± 4.6 a 4.7 ± 1.2 b 3.2 ± 1.4 b
Triglyceride, mg/dL 132.7 ± 5.8 a 110.4 ± 7.4 b 105.3 ± 5.3 b 84.6 ± 5.9 c
Cholesterol, mg/dL 139.7 ± 4.9 ab 153.4 ± 3.3 a 142.3 ± 4.9 ab 134.0 ± 4.7 b
HDL cholesterol, mg/dL 89.4 ± 2.7 92.7 ± 1.0 91.4 ± 2.0 86.8 ± 3.0
NEFA, mEq/L 1.7 ± 0.1 a 1.5 ± 0.1 ab 1.5 ± 0.1 b 1.1 ± 0.1 c
Hepatic lipids
Triglyceride, mg/g liver 14.1 ± 0.4 a 14.1 ± 0.5 a 12.9 ± 0.3 ab 11.9 ± 0.5 b
Cholesterol, mg/g liver 2.5 ± 0.2 a 2.4 ± 0.1 a 1.8 ± 0.1 b 1.7 ± 0.1 b
NEFA, 10−3 mEq/g liver 3.6 ± 0.2 b 4.6 ± 0.3 ab 4.9 ± 0.4 ab 5.6 ± 0.7 a
1 Values are mean ± S.E.M. n = 8–11 per group at eight weeks. 2 Means in each row with superscripts without
a common letter differ, p < 0.05. 3 LF: Low-fat diet. 4 HF: High-fat diet. 5 OXY1: High-fat diet supplemented with
0.25% oxyresveratrol. 6 OXY2: High-fat diet supplemented with 0.5% oxyresveratrol. 7 HOMA-IR index: fasting
serum glucose (mmol/L) × fasting serum insulin (mIU/L)/22.5.
3.4. Effects of Oxyresveratrol on mRNA Expression of Liver, Visceral Fat, and Gastrocnemius Muscle
In OXY supplemented HF groups (especially in OXY2 group), hepatic mRNA expression of
AMP-activated protein kinase α2 (AMPKα2) was upregulated, whilst glucose-6-phosphatase (G6pase)
level was downregulated compared to the HF group (Figure 3a,b). Hepatic mRNA expressions of
carnitine palmitoyltransferase IA (CPT-1a), carnitine palmitoyltransferase IB (CPT-1b) in oxyresveratrol
OXY groups were similar to those of the HF group (Figure 3c,d). Mice fed with a high-fat diet for
eight weeks had decreased mRNA expressions of glucose transporter type 4 (GLUT4) in visceral fat,
whereas GLUT4 level was upregulated in OXY supplemented HF groups (Figure 4). In gastrocnemius
muscle, mRNA expressions of GLUT4, insulin receptor substrate 1 (IRS-1), SIRT1, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), AMPKα1 and AMPKα2 were all
upregulated in OXY supplemented groups (especially in OXY2) compared to the HF group (Figure 5).
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Figure 3. Relative mRNA expression levels of AMPKα2 (a), G6Pase (b), CPT-1a (c), and CPT-1b (d)
in liver of C57bl/6 mice that were fed low-fat or high-fat diet with or without oxyresveratrol
(n = 8–11/group) for eight weeks. Values are presented as means ± S.E.M. Within each treatment, bars
topped by different letters are significantly different at p < 0.05.
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Figure 4. Relative mRNA expression level of GLUT4 in visceral fat of C57bl/6 mice that were fed
low-fat or high-fat diet with or without oxyresveratrol (n = 8–11/group) for eight weeks. Values are
presented as means ± S.E.M. Within each treat ent, bars topped by different letters are significantly
different at p < 0.05.Nutrients 2017, 9, 147  8 of 14 
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Figure 5. Relative mRNA expression levels of GLUT4 (a), IRS1 (b), SIRT1 (c), PGC-1α (d), PKα1 (e),
and AMPKα2 (e) in gastrocnemius scle of C57bl/6 mice that were fed low-fat or high-fat diet with
or it ut oxyresveratrol (n = 8–11/group) for eight weeks. Values ar presented as means ± S.E.M.
Within each treatmen , bars topped by different lett rs are significantly different at p < 0.05.
3.5. Effects of Oxyresveratrol on Hepatic Protein Expression
In liver, protein levels of sterol regulatory element-binding proteins 1 (SREBP-1), CCAAT/
Enhancer-binding proteins α (C/EBPα), and fatty acid synthase (FAS) were significantly downregulated
in OXY supplemented high-fat diets groups (Figure 6a–c,f). While no significant difference on
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CCAAT/Enhancer-binding proteins β (C/EBPβ) and peroxisome proliferator-activated receptor γ
(PPARγ) has been observed among the four mice groups (Figure 6d–f).Nutrients 2017, 9, 147  9 of 14 
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4. Discussion
In recent years, resveratrol has been demonstrated to effectively lower body weight and adiposity
in rodents fed a high-calorie diet by inducing favorable changes in specific gene and protein
expression [5]. Being similar in structure with resveratrol, OXY has been identified to hold various
biological functions that are comparable to those of resveratrol. However, little is known about its
anti-obesity property. Our previous in vitro study determined that OXY possesses anti-adipogenic
property in 3T3-L1 cells by regulating some key transcriptional factors, as well as inducing cell cycle
arrest through modulation of specific cell cycle regulatory molecules [17], which encouraged us to
study the potential effect of OXY in regulating obesity in vivo. In the present study, OXY was evaluated
of its impact on weight management, obesity-related biochemical parameters, and the regulation of
adiposity related gene and protein expression in high-fat diet-fed mice. The results clearly manifested
that, compared to the HF group, OXY supplementation remarkably induced suppression of body
weight (up to 26%), and organ weight of liver (up to 28%), and visceral fat (up to 51%), restored
serum level of glucose and insulin, and ameliorated the lipid profile of serum and liver in high-fat
diet-fed mice.
Diet composition is closely related to energy efficiency. Mice with high-fat diet induced obese
would have increased energy efficiency, partly resulting from the high energy content of triglycerides,
which are stored in essentially anhydrous form other than the hydrated form for polysaccharides,
reducing the energy stores’ efficiency as fuel [21–23]. In this study, an increase in energy efficiency has
been observed in the HF group, while OXY1 diet (2.5 g OXY/kg HF diet) decreased energy efficiency
in mice and normalized it to that of the low-fat diet group. Moreover, comparing to the OXY1 group,
mice fed with OXY2 diet (5 g OXY/kg HF diet) had significantly lower body weight gain, energy
efficiency, and visceral fat weight without changing the energy intake, which suggested that there
might be a dose dependent effect for OXY to regulate obesity.
Insulin, a peptide hormone secreted by the β cells in the pancreas, functions to suppress serum
level of glucose by catalyzing glucose transfer into adipose tissue and muscle, and reducing hepatic
glucose production [24]. Obesity development could lead to insulin resistance, characterized by the
raised level of circulating insulin, as well as suppressed insulin sensitivity [25,26]. In this study, serum
insulin level and insulin resistance index, HOMA-IR, in the HF group mice was significantly elevated
compared to those of the LF group, while OXY supplementation alleviated them in high-fat diet-fed
mice and reduced their levels to those of the LF mice.
Under the condition of insulin resistance, cells in insulin dependent tissues, principally adipose
tissues and muscles, are resistant to insulin and fail to respond to it effectively, inducing a high
level of serum glucose [27]. In this study, serum glucose level was significantly elevated in the HF
group compared to that of the LF group, while OXY supplementation significantly reduced its level.
For adipocytes and muscle cells, intracellular glucose uptake is insulin-dependent via GLUT4, a major
glucose transporter protein. Adipose tissue is supposed to account for around 10% of insulin-regulated
whole body glucose uptake [27]. Through GLUT4, excess blood glucose is diffused into adipocytes,
stimulating the synthesis of fatty acid and glycerol, while suppressing lipolysis. Similar with what
happens to adipocytes, the transportation of intracellular glucose into muscle cells is also via GLUT4
under the regulation of insulin. Muscle is the primary site of insulin-stimulated glucose disposal, and
accounts for around 60%–70% of whole body glucose uptake [27,28]. Earlier researches suggested that
GLUT4 gene expression is decreased in adipose tissue, while retained in muscle under various insulin
resistant states [28]. With the increased GLUT4 expression in adipose tissue or muscle, or both, glucose
tolerance and insulin sensitivity could be elevated in normal, obese, or diabetic mice [28]. In this study,
the mRNA expression of GLUT4 was downregulated in visceral fat, but preserved in muscles of the
HF group compared to that of the LF group, and the results are consistent with those previous studies.
Nevertheless, the OXY supplementation significantly upregulated GLUT4 expression in both visceral
fat tissue and muscle of high-fat fed mice, which might stimulate insulin sensitivity, increasing blood
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glucose uptake into adipocytes and muscle cells, reducing serum glucose level in OXY supplemented
mice groups.
Apart from GLUT4, IRS-1—a member of the insulin receptor substrate family of adaptor
molecules—also plays vital role in intracellular glucose uptake. It is involved in insulin signaling
through tyrosine phosphorylation in response to insulin, insulin growth factor-1, and cytokines [29].
The reduced insulin receptor and IRS-1 levels, their depressed tyrosine phosphorylation together
with the diminished IRS1-associated phosphatidylinositol-3 kinase activity all devote to the defective
insulin-stimulated glucose transport through impairing GLUT4 translocation in muscle in obese
subjects [30,31]. In this study, mRNA levels of IRS-1 and GLUT4 were both significantly increased in
muscle of OXY treated group (OXY2) compared to the HF group, suggesting that OXY supplementation
might increase glucose uptake and disposal in muscle through ameliorating insulin resistance by
stimulating IRS-1 and GLUT4 expression.
The decreased mRNA expression of hepatic G6Pase in the OXY supplemented groups might also
due to the ameliorated hyperglycemia. G6Pase is a multifunctional enzyme capable of hydrolyzing
glucose-6-phosphate, and producing free glucose, which is released from liver to blood [32].
The downregulation of G6Pase in OXY supplemented groups might result in the reduced production
of hepatic glucose, thus lowering the release of glucose into the bloodstream. The above results
demonstrated that hyperglycemia induced by high-fat diet in mice could be effectively alleviated by
OXY supplementation, presumably attributed to OXY’s ameliorative effect in insulin resistance by
elevating glucose uptake into peripheral tissues and depressing hepatic glycogenolysis.
During obesity development, the defective hepatic metabolism as well as the excessive adiposity
lead to an increase in plasma free fatty acids level [24]. In this study, serum triglyceride, cholesterol,
and NEFA levels, as well as hepatic triglyceride and cholesterol levels were significantly lowered in
OXY supplemented group (OXY2) compared to the HF group. In liver, the protein expressions of
SREBP-1 and FAS were both diminished in OXY supplemented groups than those of the HF group.
SREBP-1, a member of the basic helix-loop-helix leucine zipper family, regulates triglyceride synthesis
through mediating the transcription and expression of lipogenic proteins, such as FAS, which is
a multi-functional enzyme mainly involved in catalyzing the synthesis of long chain fatty acids [33,34].
OXY supplementation might reduce fat content in liver through the SREBP-1 pathway by suppressing
SREBP-1 expression and, hence diminishing FAS activity to lower fatty acid and triglyceride synthesis
and storage.
Meanwhile, the hepatic expression of C/EBPα protein was suppressed in OXY supplemented
groups compared to the HF group. C/EBPs are members of the basic leucine zipper family of
transcriptional factors and mainly function by directing the adipose-specific gene expression during
adipocyte transition process [35,36]. C/EBPα is primarily expressed in hepatocytes and adipocytes
and has been well documented to involve in energy homeostasis [37,38]. The deficiency of hepatic
C/EBPα could decrease body lipid level by diminishing the induction of lipogenic genes to reduce
hepatic TG and cholesterol concentration [38]. Therefore, apart from the SREBP-1 pathway, OXY may
also restrict hepatic lipid synthesis through the downregulation of hepatic C/EBPα.
Also, hepatic AMPKα2 expression was elevated in OXY supplemented groups. AMPK is an energy
sensing enzyme that plays a vital role in regulating metabolic homeostasis through mediating
mitochondrial biogenesis in response to energy deprivation [39]. AMPKα is a subunit of AMPK
with two isoforms—namely, AMPKα1 and AMPKα2 [31]. AMPKα1 is widely expressed, whereas
AMPKα2 is the dominant catalytic form of AMPK in the liver, muscle, and hypothalamus and essential
for the modulation of metabolic homeostasis and insulin sensitivity [40]. In liver, AMPK is capable
of suppressing hepatic glucose, free fatty acid, TG, and cholesterol synthesis by inactivating specific
gene and protein expressions in gluconeogenesis and lipogenesis [31]. In this study, the increased
hepatic AMPKα2 expression thus may be a result of the reduced hepatic glucose and lipids synthesis.
Therefore, OXY may ameliorate hepatic fat accumulation mainly through mediating the expression of
adipogenic gene/proteins (SREBP-1, FAS, C/EBPα, and AMPKα2). The alleviated hepatic metabolism
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together with the reduced adiposity in OXY supplemented groups may work collaboratively to regulate
lipid profile in serum.
In the OXY supplemented group (OXY2), muscle mRNA expressions of AMPKα, PGC-1α, and
SIRT1 were all upregulated compared to the HF group. PGC-1α, a metabolic co-activator, functions in
stimulating mitochondrial biogenesis and respiration through interacting with transcription factors [41].
It controls fiber-type switching and the expression of various genes involved in lipid oxidation and
mitochondrial metabolism [42]. AMPK can activate PGC-1α by direct phosphorylation, enhancing
its transcriptional activity [39]. Meanwhile, AMPK needs PGC-1α to regulate the expression of
several important genes involved in mitochondrial and glucose metabolism [42]. SIRT1, which is
well documented for its beneficial effect in life span extension, can also interact with PGC-1α in muscle
directly by deacetylation, promoting mitochondrial activity, thus improving exercise performance
and thermogenic activity [42,43]. In muscle, AMPK and SIRT1 work cooperatively to mediate energy
metabolism, and AMPK could enhance SIRT1 activity through upregulating cellular nicotinamide
adenine dinucleotide level, leading to the deacetylation and regulation of the activity of downstream
SIRT1 targets [39]. A recent in vivo study indicated that AMPK, PGC-1α, and SIRT1 act as an energy
sensing network to promote metabolic fitness, suggesting that OXY supplementation might benefit
metabolic homeostasis through stimulating the expression of AMPK, PGC-1α, and SIRT1 in muscle
to advance their network [42]. However, further studies are needed to verify their connections and
effects on obesity development.
5. Conclusions
OXY supplementation remarkably induced suppression on body weight (up to 26%), organ
weight of liver (up to 28%), and visceral fat (up to 51%). It restored serum level of glucose and insulin,
which was presumably through increasing intracellular glucose uptake in muscle and adipose tissue by
upregulating expression of key glucose transportation genes (GLUT4/IRS1) in these tissues, as well as
repressing free glucose production in liver by suppressing hepatic G6Pase expression. Meanwhile, lipid
profile of serum and liver was significantly ameliorated in OXY supplemented high-fat diet-fed groups,
which was presumably through mediating expression of major adipogenic genes/proteins (SREBP-1,
FAS, C/EBPα, AMPKα2) in liver. Also, OXY might promote metabolic fitness in high-fat diet-fed mice
by elevating the expressions of AMPKα, PGC-1α, and SIRT1 in muscle. To our knowledge, this is
the first study providing in vivo evidence for OXY’s anti-obesity property. Further research in other
animal models or in humans should be considered to verify OXY’s effect in counteracting obesity.
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